Techno Drugs (DHA:TECHNODRUG) Beneish M-Score: -2.50 (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:TECHNODRUG Techno Drugs Ltd DHA:TECHNODRUG
37 GF Score
Price BDT47.30
! 10 Warning Signs
View Full Analysis

What is Techno Drugs Beneish M-Score?

Techno Drugs DHA:TECHNODRUG -2.27% 37 Beneish M-Score is -2.50 as of Jul. 24, 2026. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 910 Drug Manufacturers companies, Techno Drugs ranks worse than 50.33% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.5 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Techno Drugs's Beneish M-Score or its related term are showing as below:

DHA:TECHNODRUG' s Beneish M-Score Range Over the Past 10 Years
Min: -2.55   Med: -2.5   Max: -2.4
Current: -2.5

During the past 2 years, the highest Beneish M-Score of Techno Drugs was -2.40. The lowest was -2.55. And the median was -2.50.


Techno Drugs Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Techno Drugs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Techno Drugs Beneish M-Score Chart

Techno Drugs Annual Data
Trend Jun24 Jun25
Beneish M-Score
0.00 0.00

Techno Drugs Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -2.40 -2.55 -2.50

DHA:TECHNODRUG vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Techno Drugs Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Techno Drugs's Beneish M-Score falls into.


DHA:TECHNODRUG
37GF Score
Techno Drugs Ltd DHA:TECHNODRUG
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Techno Drugs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Techno Drugs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9683+0.528 * 0.9508+0.404 * 1.1951+0.892 * 0.992+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1492+4.679 * -0.001548-0.327 * 1.0006
=-2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was BDT1,160 Mil.
Revenue was 611.89 + 830.223 + 877.87 + 781.749 = BDT3,102 Mil.
Gross Profit was 270.926 + 347.766 + 355.371 + 393.571 = BDT1,368 Mil.
Total Current Assets was BDT2,867 Mil.
Total Assets was BDT7,637 Mil.
Property, Plant and Equipment(Net PPE) was BDT4,763 Mil.
Depreciation, Depletion and Amortization(DDA) was BDT0 Mil.
Selling, General, & Admin. Expense(SGA) was BDT55 Mil.
Total Current Liabilities was BDT877 Mil.
Long-Term Debt & Capital Lease Obligation was BDT2,429 Mil.
Net Income was 40.301 + 53.395 + 61.725 + 46.987 = BDT202 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = BDT0 Mil.
Cash Flow from Operations was 68.052 + 126.563 + 19.618 + 0 = BDT214 Mil.
Total Receivables was BDT1,208 Mil.
Revenue was 660.004 + 913.512 + 1020.405 + 532.892 = BDT3,127 Mil.
Gross Profit was 280.65 + 379.916 + 416.236 + 233.998 = BDT1,311 Mil.
Total Current Assets was BDT3,430 Mil.
Total Assets was BDT7,322 Mil.
Property, Plant and Equipment(Net PPE) was BDT3,886 Mil.
Depreciation, Depletion and Amortization(DDA) was BDT0 Mil.
Selling, General, & Admin. Expense(SGA) was BDT49 Mil.
Total Current Liabilities was BDT1,579 Mil.
Long-Term Debt & Capital Lease Obligation was BDT1,589 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1160.018 / 3101.732) / (1207.718 / 3126.813)
=0.37399 / 0.386246
=0.9683

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1310.8 / 3126.813) / (1367.634 / 3101.732)
=0.419213 / 0.440926
=0.9508

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2867.048 + 4762.666) / 7637.153) / (1 - (3430.408 + 3885.523) / 7321.898)
=0.000974 / 0.000815
=1.1951

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3101.732 / 3126.813
=0.992

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 3885.523)) / (0 / (0 + 4762.666))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(55.398 / 3101.732) / (48.593 / 3126.813)
=0.01786 / 0.015541
=1.1492

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2429.084 + 877.263) / 7637.153) / ((1588.619 + 1579.419) / 7321.898)
=0.432929 / 0.43268
=1.0006

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(202.408 - 0 - 214.233) / 7637.153
=-0.001548

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Techno Drugs has a M-score of -2.50 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.50 mean?
Techno Drugs (DHA:TECHNODRUG) has a Beneish M-Score of -2.50 as of Jul. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Techno Drugs and its competitors. According to the industry distribution chart, Techno Drugs ranks #458 out of 910 companies in the Drug Manufacturers industry, placing it in the top 50.3%.
Is Techno Drugs' Beneish M-Score too high?
Techno Drugs' current Beneish M-Score is -2.50. Based on the distribution chart, Techno Drugs ranks #458 out of 910 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #458 out of 910 companies for Beneish M-Score. This places Techno Drugs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Techno Drugs and its competitors. Techno Drugs's current Beneish M-Score is -2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Beneish M-Score of -2.50. The current Beneish M-Score is -2.50. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Beneish M-Score is -2.50 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Techno Drugs Business Description

Address 31 Segun Bagicha, J K Tower, Dhaka, BGD, 1000
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score

Get the complete analysis for DHA:TECHNODRUG

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT47.30
Price